Similar articles

• MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities.

  Chen SN, Chang R, Lin LT, Chern CU, Tsai HW, Wen ZH, Li YH, Li CJ, Tsui KH. Chen SN, et al. Int J Environ Res Public Health. 2019 Apr 29;16(9):1510. doi: 10.3390/ijerph16091510. Int J Environ Res Public Health. 2019. PMID: 31035447 Free PMC article. Review.
• Ovarian cancer: opportunity for targeted therapy.

  Tagawa T, Morgan R, Yen Y, Mortimer J. Tagawa T, et al. J Oncol. 2012;2012:682480. doi: 10.1155/2012/682480. Epub 2011 Dec 22. J Oncol. 2012. PMID: 22235203 Free PMC article.
• SiRNA and epigenetic aberrations in ovarian cancer.

  Mirzaei H, Yazdi F, Salehi R, Mirzaei HR. Mirzaei H, et al. J Cancer Res Ther. 2016 Apr-Jun;12(2):498-508. doi: 10.4103/0973-1482.153661. J Cancer Res Ther. 2016. PMID: 27461600 Review.
• Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.

  Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd. Jones MB, et al. Proteomics. 2002 Jan;2(1):76-84. Proteomics. 2002. PMID: 11788994
• Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.

  Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. Chien JR, et al. J Cell Biochem. 2007 Dec 1;102(5):1117-29. doi: 10.1002/jcb.21552. J Cell Biochem. 2007. PMID: 17879946 Review.